103 related articles for article (PubMed ID: 22971185)
1. Preclinical evaluations of norcantharidin-loaded intravenous lipid microspheres with low toxicity.
Lin X; Zhang B; Zhang K; Zhang Y; Wang J; Qi N; Yang S; He H; Tang X
Expert Opin Drug Deliv; 2012 Dec; 9(12):1449-62. PubMed ID: 22971185
[TBL] [Abstract][Full Text] [Related]
2. Liquid chromatography-tandem mass spectrometry evaluation of the pharmacokinetics of a diacid metabolite of norcantharidin loaded in folic acid-targeted liposomes in mice.
Liu MC; Ma XQ; Xu Y; Peng LH; Han M; Gao JQ
J Pharm Biomed Anal; 2016 Feb; 119():76-83. PubMed ID: 26658337
[TBL] [Abstract][Full Text] [Related]
3. A highly stable norcantharidin loaded lipid microspheres: preparation, biodistribution and targeting evaluation.
Ma J; Teng H; Wang J; Zhang Y; Ren T; Tang X; Cai C
Int J Pharm; 2014 Oct; 473(1-2):475-84. PubMed ID: 25089504
[TBL] [Abstract][Full Text] [Related]
4. A stable and practical etoposide-containing intravenous long-/medium-chain triglycerides-based lipid emulsion formulation: pharmacokinetics, biodistribution, toxicity, and antitumor efficacy.
Dong W; Zhang L; Niu Y; Fan D; Wu X; Tang X; Cai C
Expert Opin Drug Deliv; 2013 May; 10(5):559-71. PubMed ID: 23373755
[TBL] [Abstract][Full Text] [Related]
5. PEGylated lipid microspheres loaded with cabazitaxel for intravenous administration: stability, bioavailability, antitumor efficacy, and toxicity.
Liu Y; Xie B; Li L; Zhang X; Zhang Y; He H; Yin T; Tang X; Cai C; Gou J
Drug Deliv Transl Res; 2018 Oct; 8(5):1365-1379. PubMed ID: 30019282
[TBL] [Abstract][Full Text] [Related]
6. [In vitro and in vivo assesemet of sodium norcantharidin lipid microsphere].
Wang LX; He HB; Tang X; Shao RY; Wang J; Chen DW
Yao Xue Xue Bao; 2006 Aug; 41(8):784-8. PubMed ID: 17039788
[TBL] [Abstract][Full Text] [Related]
7. A less irritant norcantharidin lipid microspheres: formulation and drug distribution.
Lixin W; Haibing H; Xing T; Ruiying S; Dawei C
Int J Pharm; 2006 Oct; 323(1-2):161-7. PubMed ID: 16828998
[TBL] [Abstract][Full Text] [Related]
8. [Studies on the liver targeting of norcantharindin microemulsion].
Zhang L; Xiang D; Hong Z; Zhang ZR
Yao Xue Xue Bao; 2004 Aug; 39(8):650-5. PubMed ID: 15563071
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers.
Li F; Weng Y; Wang L; He H; Yang J; Tang X
Int J Pharm; 2010 Jun; 393(1-2):203-11. PubMed ID: 20385221
[TBL] [Abstract][Full Text] [Related]
10. Preparation, characterization and anticancer activity of norcantharidin-loaded poly(ethylene glycol)-poly(caprolactone) amphiphilic block copolymer micelles.
Chen SF; Lu WF; Wen ZY; Li Q; Chen JH
Pharmazie; 2012 Sep; 67(9):781-8. PubMed ID: 23016451
[TBL] [Abstract][Full Text] [Related]
11. Determination and pharmacokinetic study of the diacid metabolite of norcantharidin in beagle plasma by use of liquid chromatography-tandem mass spectrometry.
Liu M; Ma X; Jin Z; Li W; Guo M; Li F
Anal Bioanal Chem; 2013 Nov; 405(28):9273-83. PubMed ID: 24096565
[TBL] [Abstract][Full Text] [Related]
12. [Effects of norcantharidin on angiogenesis of human gallbladder carcinoma and its anti-angiogenic mechanisms].
Fan YZ; Chen CQ; Zhao ZM; Sun W
Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(10):693-9. PubMed ID: 16681930
[TBL] [Abstract][Full Text] [Related]
13. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ
Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, tissue distribution, and metabolites of a polyvinylpyrrolidone-coated norcantharidin chitosan nanoparticle formulation in rats and mice, using LC-MS/MS.
Ding XY; Hong CJ; Liu Y; Gu ZL; Xing KL; Zhu AJ; Chen WL; Shi LS; Zhang XN; Zhang Q
Int J Nanomedicine; 2012; 7():1723-35. PubMed ID: 22619523
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of docetaxel-loaded intravenous lipid emulsion: pharmacokinetics, tissue distribution, antitumor activity, safety and toxicity.
Zhao M; Su M; Lin X; Luo Y; He H; Cai C; Tang X
Pharm Res; 2010 Aug; 27(8):1687-702. PubMed ID: 20552255
[TBL] [Abstract][Full Text] [Related]
16. Development of intravenous lipid emulsion of vinorelbine based on drug-phospholipid complex technique.
Li Y; Jin W; Yan H; Liu H; Wang C
Int J Pharm; 2013 Sep; 454(1):472-7. PubMed ID: 23806812
[TBL] [Abstract][Full Text] [Related]
17. Primary in vitro and in vivo evaluation of norcantharidin-chitosan/poly (vinyl alcohol) for cancer treatment.
Li M; Xu X; Lu F; Guo S
Drug Deliv; 2014 Jun; 21(4):293-301. PubMed ID: 24156408
[TBL] [Abstract][Full Text] [Related]
18. Determination of norcantharidin in mouse tissues by liquid chromatography coupled to tandem mass spectrometry and its tissue distribution study.
Zhang R; Wang J; Yuan G; Wei C; Liu X; Wang B; Gao H; Guo R
Arzneimittelforschung; 2012 Jun; 62(6):290-4. PubMed ID: 22473525
[TBL] [Abstract][Full Text] [Related]
19. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system.
Lee SW; Yun MH; Jeong SW; In CH; Kim JY; Seo MH; Pai CM; Kim SO
J Control Release; 2011 Oct; 155(2):262-71. PubMed ID: 21704664
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of acute toxicity of two preparations of norcantharidin in mice].
Li B; Zhu LF; Zhang YN; Gu W
Zhong Xi Yi Jie He Xue Bao; 2007 Jan; 5(1):74-7. PubMed ID: 17214941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
